NCT00900588View on ClinicalTrials.gov

Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Adolescents

PHASE2CompletedINTERVENTIONAL

Timeline

Start Date

Not specified

Conditions

Influenza

Interventions

BIOLOGICAL

split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)

Trial Locations (1)

100013

Beijing Centers for Diseases Control and Prevention, Beijing

All Listed Sponsors

collaborator

Centers for Disease Control and Prevention, China

OTHER_GOV

lead

Sinovac Biotech Co., Ltd

INDUSTRY